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Objective: Dopa-responsive dystonia (DRD) is a rare form of hereditary movement disorder
with onset in childhood, characterized by gait difﬁculties due to postural dystonia with
marked improvement after low doses of levodopa. Mutations in the GCH1 gene are the most
common cause of DRD, however, in some cases when the disease is associated with
parkinsonism mutations in the PARK2 gene may be identiﬁed. The aim of this study was
to analyze and compare genotype–phenotype correlation.
Material/participants: Four families with inter- and intrafamilial variability of progressive gait
dysfunction due to lower limb dystonia occurring in childhood or adolescence were included
in the analysis.
Methods: General and neurological examination was performed for all affected family
members and asymptomatic mutation carriers. The molecular analysis encompassed
GCH1 and PARK2 genes.
Results: All probands were clinically diagnosed with DRD. The molecular analysis revealed,
however, that the dopa-responsive dystonia phenotype was caused by a mutation in the
GCH1 gene in three families and in the PARK2 gene in one family. Obtained results allowed
to establish the ﬁnal diagnosis for all families as DYT5a or early-onset Parkinson disease
(EO-PD).
Conclusions: Reported cases conﬁrm that the DRD phenotype may have heterogeneous
genetic background and may be caused by point mutations or rearrangements in the
GCH1 gene as well as in the PARK2 gene. Differential diagnosis and genetic tests covering
the analysis of genes causative for DRD and EO-PD should be obligatory in both disorders
diagnostics as DRD, mainly adolescent onset dystonia, may be associated with parkinsonism.
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Generalized dystonia is a rare form of hereditary movement
disorder with onset in childhood, characterized by postural
dystonia with marked diurnal ﬂuctuations. Dystonia may
be difﬁcult to diagnose correctly because of its many
presentations. However, the excellent response to low doses
of levodopa (L-dopa) suggests the clinical diagnosis of Segawa
disease, known also as dopa-responsive dystonia (DRD) or
DYT5 (MIM 128230) [1]. DRD usually starts as foot dystonia
causing gait disorder with diurnal ﬂuctuations, and subse-
quent overﬂow of dystonic movements to other muscles
and parts of the body. Atypical symptoms such as delayed
and awkward gait (walking on toes) have also been reported
[2]. That is why DRD patients may be misdiagnosed as
having spastic diplegic cerebral palsy, intractable epilepsy,
hereditary spastic paraplegia or a neurodegenerative disor-
der [3].
The most frequent type of DRD, referred as DYT5a, is
inherited as an autosomal dominant trait with reduced
penetrance, caused by mutations in the GCH1 gene (MIM
600225) coding for GTP cyclohydrolase I – GCH1 (MIM 600225),
and distinguished from the recessive form DYT5b caused by
mutations in the TH gene (MIM 191290) coding for tyrosine
hydroxylase – TH (MIM 191290). Both enzymes are involved in
L-dopa synthesis pathway [3]. Additionally homozygous and
heterozygous mutations of the sepiapterine reductase coding
gene – SPR (MIM 182125) were described in DRD cases with wide
spectrum of severity course and early onset (MIM 612716) [4].
Generally in all those types of DRD the metabolism ofFig. 1 – Pedigree chart for the patients with dopa-responsive dys
& indicates male, * represents female, * or & denotes affected
or * denotes asymptomatic members.dopamine is markedly disturbed as a consequence of reduced
synthesis and activity of TH.
It is worth emphasizing that DRD, mainly of adolescent
onset, may be associated with parkinsonism. In these cases
differential diagnosis of early-onset Parkinson disease (EO-PD)
(MIM 600116) due to the PARK2 gene (MIM 600544) mutation
should also be considered in a diagnostic algorithm.
Recent retrospective analysis of the published data on DRD
(101 papers) [5] has indicated, that despite the well-known
etiology of the disease and availability of genetic testing, there
is still marked delay in its deﬁnitive diagnosis in many cases.
In some patients lack of timely therapy may lead to residual
motor or nonmotor signs (depression, anxiety, obsessive-
compulsive disorder), and other complications, even if the
proper treatment is ﬁnally introduced.
2. Materials and methods
2.1. Subjects
We present four families (Fig. 1) with progressive gait
dysfunction due to lower limb dystonia occurring in childhood
or adolescence with detailed clinical and neurological exami-
nation. One person, a specialist of movement disorders, in an
academic high reference hospital, examined all patients.
Additional diagnostic tests excluded secondary movement
disorders including Wilson's disease (ceruloplasmine level),
acanthocytosis and thyroid dysfunction in all of them. Their
brain MR scans, EMG and basic laboratory measurements
(biochemistry and morphology) were normal.tonia phenotype and their families with revealed mutations.
 individuals, arrow indicates proband. A mutation beside &
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The molecular analysis of two genes, GCH1 and PARK2, was
performed for all probands, and an appropriate gene was
analyzed in their relatives. Genomic DNA was extracted from
venous blood using standard methods. Because sequence
variants and exonic or whole gene deletion/duplications in
both genes are known as pathogenic, two methods were used,
the direct sequencing of all exons and exon/intron boundaries
(intronic primers were used, sequence available on request)
and Multiplex Ligation-dependent Probe Ampliﬁcation (MLPA,
SALSA MLPA Kit P051-B1/P052-C1 Parkinson; MRC Holland
b.v.). Sequencing was the ﬁrst step of the GCH1 gene analysis,
as sequence variants in this gene are identiﬁed in about 60% of
DRD cases [6], while for the PARK2 the frequency of both types
of mutations is equal [7].
Sequence was analyzed using Mutation Surveyor® v.3.24
software (Softgenetics LLC) in comparison to the CGH1 and
PARK2 reference sequences NM_018105 and NM_004562.2
(NCBIRefSeq; http://www.ncbi.nlm.nih.gov/nuccore). The
Gene Marker v.1.51 software (SoftGenetics LLC) was used to
MLPA dosage ratio analysis (standard parameters, dosage
ratio boundaries <0.75 and >1.25 for deletion and duplication
respectively). The whole GCH1 gene deletion and exonic
deletion in the PARK2 gene were conﬁrmed by the array-
comparative genomic hybridization (aCGH) using, the chro-
mosome 6 and 14 NimbleGen 385 Tiling Array HG18, NCBI 36
(Roche NimbleGen Inc.) respectively. Genome positions of the
rearrangements were speciﬁed according to Human Mar.2006
(NCBI36/hg18) assembly [University of California, Santa Cruz
Genome Browser, http://genome.ucsc.edu].
Mutations identiﬁed for probands were analyzed in their
family members (Fig. 1): Fam.1 GCH1 exon 2 sequencing (3
persons), Fam.2 MLPA P052 (5 persons), Fam.3 MLPA P052 (3
persons), Fam.4 PARK2 exon 2 sequencing and MLPA P051/P052
(4 persons) and the whole gene analysis for the proband's
partner.
All subjects signed the informed consent to perform
appropriate molecular tests.
3. Results
3.1. Clinical characterization
Results of clinical and neurological testing and response to L-
dopa treatment are presented in Table 1.
3.2. Molecular characterization
Molecular background of the DRD phenotype was conﬁrmed in
all families. In three probands the heterozygous mutations in
the GCH1 gene and in one the biallelic mutation in the PARK2
gene were identiﬁed. Obtained results allowed to establish
ﬁnal diagnosis for all those families, as DYT5a in the cases of
Fam.1, 2, 3 and EO-PD in Fam.4.
Family 1 (Fig. 1 and Table 1; Fam.1): The diagnosis of the
DYT5a was established according to the GCH1 gene sequenc-
ing results, which revealed the heterozygous substitution
in position c.453+1G>A; proband's genotype c.[453+1G>A];[=],p[?];[=]. This mutation has already been reported in DRD [8].
Identiﬁed substitution is located in the conservative donor
splice site of intron 2 and is likely to result in the exon 2
skipping and frame shift mutation, followed by premature
STOP codon generation, as suggested previously [9]. Proband's
mother and maternal grandmother were also carriers of this
mutation. However, their medical history and neurological
examination data demonstrate incomplete penetrance of the
mutation resulting in the intrafamilial variability of the
disorder's clinical picture (Table 1).
Family 2 (Fig. 1 and Table 1; Fam.2): This family was also
diagnosed as DYT5a but due to a partial deletion of the GCH1
gene. The MLPA analysis performed for proband identiﬁed the
deletion of exons 1, 2, 3, 5 and 6 (there is no probe for exon 4 in
the P052 kit); proband's genotype c.[-360-?_668+?del];[=], p[?];
[=]. The aCGH analysis conﬁrmed the deletion of 156 kb on one
chromosome in locus 14q22, covering the whole GCH1 and the
part of the WDHD1 gene (array14(54,376,281-54,532,230)  1).
The MLPA analysis revealed the same mutation in the
proband's siblings.
Family 3 (Fig. 1 and Table 1; Fam.3): Sequencing of the
proband's GCH1 gene revealed no point mutations, but the
deletion of exons 3 and 5 were identiﬁed with MLPA method
suggesting loss in one allele of the gene minimal region of
14 kb covering exons 3, 4 and 5 – proband's genotype c.[454-?
_c.626+?del];[=], p.[?];[=]. MLPA performed in the proband's
parents conﬁrmed maternal inheritance of the mutation.
Family 4 (Fig. 1 and Table 1; Fam.4): The molecular analysis
showed no mutation in the GCH1 gene in this family
excluding the DYT5a diagnosis. Two heterozygous, biallelic
mutations were found in the PARK2 gene, the dinucleotide AG
deletion in the exon 2 and the deletion of exons 3–4 (c.172-?
_534+?del), what allowed diagnosing EO-PD in the proband.
The deletion c.101_102del creates a frameshift starting at
codon Gln34 and STOP codon four positions downstream
p.Gln34Argfs*5; proband's genotype c.[101_102del];[172-?_534
+?del], p.[Gln34Argfs*5];[?]. Exons deletion identiﬁed by MLPA
was conﬁrmed by the aCGH analysis showing the deletion in
one allele of 176 kb fragment covering whole exons 3 and 4
(array6(162.514,594-162,691,028)  1). The PARK2 gene analy-
sis performed in the proband's parents conﬁrmed biallelic
character of mutations, other tested family members were
not carriers of identiﬁed mutations.
4. Discussion
The presented four families, with progressive gait dysfunc-
tion due to lower limb dystonia occurring in childhood or
adolescence and a good response to low doses of L-dopa, were
clinically diagnosed with DRD. Results of the molecular
analysis, however, brought on veriﬁcation of this diagnosis.
We identiﬁed among the probands mutations in the GCH1
gene, what conﬁrmed the DRD diagnosis – DYT5a, but also
the mutations in the PARK2 gene, what changed the
diagnosis to EO-PD. The problem in distinguishing between
those two forms of dopa-responsive disorders is not a new
one and has already been raised and reported [1,10–12]. The
question is, what kind of symptoms and signs might be
important and helpful in better qualiﬁcations of the DRD
Table 1 – Clinical characterization of the probands and their relatives from the presented families with DRD due to
mutations in the GCH1 and PARK2 genes.
Patients Motor
development
Age of
onset
[years]
Presenting symptom
and main features
Neurological
examination
Treatment Other
characteristic
ﬁndings
Fam.1 – CGH1 c.[453+1G>A];[=], p.[?];[=]
IV-1 Normal, but
never crawled
7 Gait difﬁculties,
diurnal ﬂuctuation
with aggravation of
symptoms toward the
evening, she was not
able to walk
unsupported
Dystonic rotation of her
left feet and abnormal
posture of her trunk
Marked clinical
improvement after
50 mg L-dopa
+ benseraside
Dyskinesia
after 100 mg
L-dopa
II-1 Normal Unknown-
adolescence?
Fatigue, limb stiffness
and gait difﬁculties
Bradykinesia with amimic
face, forward bending of
the trunk and hypokinesia
observed during
alternating movements of
the both hands
Improvement after
100 mg L-dopa
+ benseraside
No dyskinesia
IV-2 Normal 6 Gait difﬁculties Dystonic rotation of her
left feet
Symptoms
withdraw after
50 mg L-dopa/day
Not seen
Fam.2 – CGH1 c.[-360-?_668+?del];[=], p[?];[=]
II-4 Normal 5 Gait difﬁculties – she
was not able to walk
unsupported and
complained of fatigue
Not available at the onset,
at the age of 19: dystonic
rotation of her both feet
and abnormal posture of
her trunk, dystonic
movements of the both
upper limbs
Symptoms
withdraw after
100 mg L-dopa
Not seen
II-5 ND 7 Gait difﬁculties Not available at the onset Symptoms
withdraw after
100 mg L-dopa
Not seen
II-6 ND 7 Gait difﬁculties Not available at the onset Occasionally
100 mg L-dopa
Not seen
Fam.3 CGH1 – c.[454-?_626+?del];[=], p[?];[=]
III-1 Normal 5 Gait difﬁculties and
fatigue
During neurological
examination at the age of
10 she presented with left
feet dystonic posture
aggravated by the gait and
dystonic rotation of her
left hand
Marked
improvement after
50 mg L-dopa
+ 12.5 mg
benseraside
3times daily
Not seen
Fam.4 PARK2 – c.[102-102del];[172-?_534+?del], p.[Gln34Argfs*5];[?]
II-1 Normal 15 Gait difﬁculties and
pain in lower limb, at
the age of 22 she
noticed progression of
the symptoms and she
started to fall down
after long walk
During neurological
examination at the age of
28 she presented with left
feet dystonic posture
aggravated by the gait
Improvement
(with residual
slight gait
abnormalities)
after 100 mg
L-dopa + 25 mg
benseraside 3times
daily
Not seen
ND – no data
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like to discuss here.
In Fam.2 and 3, where partial and whole GCH1 gene
deletions were identiﬁed, probands present with typical
symptoms of DRD alleviated by low doses of L-dopa. Deletions
in the GCH1 gene were previously identiﬁed as causative of a
very similar phenotype as described in probands here [13].
However, among the mutation carriers, we observe the
intrafamilial heterogeneity of the clinical picture, indicating
its reduced penetrance, as it was previously described for
DYT5a [10]. In Fam.3 the probands' mother being a carrier ofthe mutation has been asymptomatic to date. In Fam.1, before
molecular conﬁrmation of DRD, a diagnosis of EO-PD was also
considered as dyskinesias were observed after the initiation of
the proband's treatment with L-dopa. Additionally the pro-
band's grandmother (Fam.1 II-1) showed typical for PD motor
symptoms such as bradykinesia, hypokinesia, amimic face
and camptocormia.
Dyskinesias may be present in patients with GCH1-
deﬁcient DRD at the initiation of L-dopa therapy, especially
if doses are relatively high or increased rapidly, but they
subside after reducing the dosage and do not reappear with
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some GCH1 mutations like in frame deletion in exon 1
c.235_240delCTGAGC/p.Leu79_Ser80del cause persistent treat-
ment limiting dyskinesias, which may develop after few years
of continuous L-dopa therapy [16]. Some patients may also
present with DRD showing atypical symptoms such as hand
tremor, spastic paraplegia, rigidity [11,12,15]. In previously
published studies the mutation in the GCH1 gene causing DRD-
plus syndrome, parkinsonism has also been reported [17,18].
The presence of gait difﬁculties in adolescence (probably due
to dystonia) and parkinsonism in adulthood, as we observed in
subject II-1 in Fam.1 (proband's grandmother) revise the
question of non-treated DRD late symptomatology. In a recent
study 4 patients presenting with adult-onset parkinsonism,
positive family history of DRD and the GCH1 mutations were
described. They fully met the UK Parkinson's Disease Society
Brain Bank (UKPDSBB) clinical criteria, had imaging evidence
of nigrostriatal dopaminergic denervation and were diagnosed
as neurodegenerative PD. This implies that the GCH1 gene
mutations may be associated not only with the parkinsonian
phenotype but also with an increased risk of PD, by 7-hold on
average according to Mencacci et al. [19] Analysis of 576 cases
[5] indicates that DRD ﬁrst symptoms start more frequently in
the lower limbs than in the upper limbs and neck in early-
onset cases (0–14 years old), as compared with the late-onset
cases (over 15 years old) where parkinsonism is more
common.
Our study shows that the mutation of the GCH 1 gene may
cause dystonia with L-dopa induced dyskinesia (Fam.1 IV-1),
while the PARK 2 mutation (Fam.4 II-1) may present with
dystonia but no parkinsonism or treatment related dyskinesia.
Mutations we identiﬁed in Fam.4 proband may cause the
classical phenotype of EO-PD not the DRD phenotype [7,20,21].
EO-PD is generally characterized by a good response to L-dopa
and a rather benign course. Dystonia, hyperreﬂexia, and
psychiatric features may be present, however, isolated leg
dystonia as a presenting symptom has not been reported to
date [22]. Mutations of the PARK2 gene have been reported as
causative for some GCH1 mutation-negative DRD cases [11].
There are some differences between DRD and EO-PD that
can be pointed out comparing the presented cases of four
families. First, the families with genetically conﬁrmed DRD
(DYT5a) had very similar age of the disease onset in contrast to
the patient with the PARK2 mutation (proband's age onset 5–7
vs 15 years old). Diurnal ﬂuctuation with aggravation of the
symptoms toward the evening, one of the most characteristic
feature of DRD, was very signiﬁcant in the patient IV-1 Fam.1
and also present but less demonstrated by other patients with
DRD unlike the patient II-1 Fam.4. The degree of ﬂuctuation
may differ among patients and attenuates with the disease
progression [6]. In DRD families symptoms disappeared almost
completely after starting the L-dopa therapy, while in EO-PD
signiﬁcant clinical improvement was observed but the patient
experienced mild residual gait difﬁculties.
The linkage between DRD and EO-PD is still debated and
further studies of these two conditions are needed. DRD
patients show normal 18-ﬂuorodopa (18F-dopa) uptake in the
positron emission tomography (PET) [23] and in most cases
normal dopamine transporter (DAT) imaging nigrostriatal
neurons in the single photon emission computed tomography(SPECT) [24], however, distinct reduction of DAT has been
reported and is associated with nigrostrial dopaminergic
denervation [19,25,26]. This implies that mild parkinsonian
symptoms, with an excellent response to low dosages of L-
dopa and a reduced uptake in the [123I] FP-CIT-SPECT
(DaTSCAN) may be more commonly seen in the GCH1
mutation carriers than previously supposed. Neuropatholog-
ical data in DRD are limited, however, it appears that in the
substantia nigra there is a reduction of melanin pigment more
pronounced in the lateral compared to the medial aspect, in a
pattern similar to the neuronal loss in PD [27]. The difference
is that there is no evidence of Lewy bodies in the substantia
nigra in DRD [28]. However, there is no atrophy of dopami-
nergic and noradrenergic neurons in the nigra and the locus
coeruleus.
Our cases indicate that the DRD phenotype can be caused
by a point mutation or rearrangements in both, the GCH1 and
the PARK2, genes. Therefore genetic tests should be obligatory
in the diagnostics of both DRD and EO-PD. Moreover, patients
with parkinsonism, especially EO-PD, if mutations in known
causative genes – PARK2, DJ-1 and PINK1 – are excluded,
should be also tested for a genetic mutation characteristic for
dystonia.
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